Engaging in urologic advocacy.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Engaging in urologic advocacy.
Συγγραφείς:	Pavuluri H; Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana., Plana-Masiques E; European Association of Urology, Policy Office, Brussels, Belgium., Collen S; European Association of Urology, Policy Office, Brussels, Belgium., Talwar R; Vanderbilt Health, Department of Urology and Department of Population Health, Nashville, Tennessee, USA.
Πηγή:	Current opinion in urology [Curr Opin Urol] 2026 Jul 01; Vol. 36 (4), pp. 417-422. Date of Electronic Publication: 2026 May 14.
Τύπος έκδοσης:	Journal Article; Review
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9200621 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-6586 (Electronic) Linking ISSN: 09630643 NLM ISO Abbreviation: Curr Opin Urol Subsets: MEDLINE
Imprint Name(s):	Publication: 1999- : Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: London, UK : Current Science Ltd., c1991-
Ιατρικοί όροι (MeSH):	Urology/legislation & jurisprudence , Urology/organization & administration , Urology/education , Urology/economics , Health Policy/legislation & jurisprudence , Urologists/legislation & jurisprudence , Urologists/education , Urologists/organization & administration , Patient Advocacy*/legislation & jurisprudence, Humans ; United States ; Policy Making ; European Union
Περίληψη:	Purpose of Review: Health policy and political decision-making increasingly shape reimbursement, technology access, workforce capacity, and research funding in urology. Despite these growing influences, many urologists receive little formal training in advocacy. This review is timely given ongoing reimbursement reform, regulatory shifts, cancer policy initiatives, and cross-border health legislation in both the United States and the European Union (EU). Recent Findings: Recent literature highlights declining procedural reimbursement, workforce shortages, and regulatory barriers to innovation in the United States, alongside expanding EU-level influence in public health, data governance, research funding, and cancer screening policy. Case studies, including reform of vaginal estrogen labeling, Veterans' prostate cancer legislation, and EU prostate cancer screening recommendations, demonstrate how coordinated clinician advocacy can directly shape policy outcomes. Professional societies and policy offices increasingly serve as structured channels for specialty engagement. Summary: Advocacy is emerging as a core professional competency for urologists. Structured engagement at institutional, national, and supranational levels enables clinicians to align policy with clinical realities, promote equitable access, and safeguard innovation. Integrating policy literacy into urologic training may strengthen the specialty's ability to influence sustainable, evidence-based health systems. (Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.)
References:	Liepert AE, Douglas A, Johns A, et al. The importance of young surgeons in surgical health policy advocacy engagement. Surgery 2026; 192:110066. Frank JR, Snell L, Sherbino J, editors. CanMEDS 2015 physician competency framework . Ottawa (ON): Royal College of Physicians and Surgeons of Canada; 2015. Benstead K, Brandl A, Brouwers T, et al. An inter-specialty cancer training programme curriculum for Europe. Eur J Surg Oncol 2023; 49:106989. Edmonds VS, Haglin JM, Tyson MD. Declining Medicare reimbursement for urologists: an opportunity for informed advocacy. J Urol 2021; 206:10–12. Kuehne F, Kalkman L, Joshi S, et al. Healthcare provider advocacy for primary health care strengthening: a call for action. J Prim Care Community Health 2022; 13:21501319221078379. Nolazco JI. Urology workforce shortage: a present challenge, a future catastrophe. Curr Urol 2025; 19:357–358. Clarke H. Experts urge FDA to remove black box warning on low-dose vaginal estrogen. Urology Times 2025; August 26 https://www.urologytimes.com/view/experts-urge-fda-to-remove-black-box-warning-on-low-dose-vaginal-estrogen . FDA announces removal of black box warning on low-dose vaginal estrogen – American Urological Association . https://www.auanet.org/advocacy/get-involved/comment-letters-and-resources/fda-announces-removal-of-black-box-warning-on-low-dose-vaginal-estrogen. National Cancer Institute. SEER*Explorer: an interactive website for SEER cancer statistics. Surveillance Research Program; 2023 April 19 [updated: 2023 Jun 8; cited 2023 Jun 23]. Available at: https://seer.cancer.gov/statistics-network/explorer/ [Accessed June 23, 2023]. Text – H.R.6092 – 116th Congress (2019–2020): Veteran's Prostate Cancer Treatment and Research Act. 2020, September 23. https://www.congress.gov/bill/116th-congress/house-bill/6092/text/eh . European Union. Consolidated version of the Treaty on the Functioning of the European Union. Part Three: union policies and internal actions – Title XIV: public health – Article 168 (ex Article 152 TEC). 2008. Available at: http://data.europa.eu/eli/treaty/tfeu_2008/art_168/oj . European Commission. Europe's Beating Cancer Plan. 2021. Available at: https://health.ec.europa.eu/system/files/2022-02/eu_cancer-plan_en_0.pdf . European Union. Consolidated version of the Treaty on the Functioning of the European Union. Part Three: union policies and internal actions – Title VII: common rules on competition, taxation and approximation of laws – Chapter 3: approximation of laws – Article 114 (ex Article 95 TEC) [Internet]. 2008. Available at: http://data.europa.eu/eli/treaty/tfeu_2008/art_114/oj . Greer SL, Rozenblum S, Fahy N, et al. , editors. Everything you always wanted to know about European Union health policy but were afraid to ask . 3rd, rev. ed. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2022. Available at: https://eurohealthobservatory.who.int/publications/i/everything-you-always-wanted-to-know-about-european-union-health-policies-but-were-afraid-to-ask-fourth-revised . European Parliament and Council of the European Union. Regulation (EC) No. 1907/2006 of 18 December 2006 concerning the registration, evaluation, authorisation and restriction of chemicals (REACH). 2006. Available at: http://data.europa.eu/eli/reg/2006/1907/oj . European Commission. Horizon Europe. 2025 [cited 2025 Nov 24]. Available at: https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe_en . European Parliament and Council of the European Union. Regulation (EU) 2021/522 of 24 March 2021 establishing a programme for the Union's action in the field of health (‘EU4Health Programme’) for the period 2021–2027. 2021 March 24. Available at: http://data.europa.eu/eli/reg/2021/522/oj . SAPEA. Improving cancer screening in the European Union. 2022. Available at: https://scientificadvice.eu/advice/improving-cancer-screening-in-the-european-union/ . Council of the European Union. Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening replacing Council Recommendation 2003/878/EC (2022/C 473/01). 2022 December 9. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32022H1213(01 ). Joint Research Centre. Cancer screening, diagnosis and care. 2025 [cited 2025 Nov 24]. Available at: https://cancer-screening-and-care.jrc.ec.europa.eu/en . European Association of Urology. Patient Office EPAG. 2025 [cited 2025 Nov 24]. Available at: https://uroweb.org/offices/patient-office-epag . European Parliament. European Parliament. [cited 2025 Nov 24]. Available at: https://www.europarl.europa.eu/portal/en . European Commission. European Commission. [cited 2025 Nov 24]. Available at: https://commission.europa.eu/index_en . European Medicines Agency. European Medicines Agency. [cited 2025 Nov 24]. Available at: https://www.ema.europa.eu/en/homepage . Biomedical Alliance in Europe. 2025 [cited 2025 Nov 24]. Available at: https://www.biomedeurope.org/ . European Cancer Organisation. 2025 [cited 2025 Nov 24]. Available at: https://www.europeancancer.org/ . Bishop C, Rodriguez-Cairoli F, Hagens A, et al. Prevalence, socioeconomic, and environmental costs of urinary incontinence in the European Union. Eur Urol 2025; 88:157–166. OPTIMA Consortium. OPTIMA – Tackling Cancer through Real World Data. [cited 2025 Dec 2]. Available at: https://www.optima-oncology.eu/ . Omar MI, Roobol MJ, Ribal MJ, et al. Introducing PIONEER: a project to harness big data in prostate cancer research. Nat Rev Urol 2020; 17:351–362. European Parliament and Council of the European Union. Regulation (EU) 2017/746 of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU. 2017 April 5. Available at: https://eur-lex.europa.eu/eli/reg/2017/746/oj/eng. European Parliament and Council of the European Union. Regulation (EU) 2021/2282 of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU. 2021 December 15. Available at: https://eur-lex.europa.eu/eli/reg/2021/2282/oj/eng .
Contributed Indexing:	Keywords: advocacy; health policy; public policy
Entry Date(s):	Date Created: 20260516 Date Completed: 20260608 Latest Revision: 20260608
Update Code:	20260608
DOI:	10.1097/MOU.0000000000001407
PMID:	42142386
Βάση Δεδομένων:	MEDLINE

Περιγραφή
ISSN:	1473-6586
DOI:	10.1097/MOU.0000000000001407